51.50
-0.12(-0.23%)
Currency In USD
| Previous Close | 51.62 |
| Open | 51.66 |
| Day High | 52.77 |
| Day Low | 50.58 |
| 52-Week High | 57.88 |
| 52-Week Low | 14.8 |
| Volume | 735,131 |
| Average Volume | 1.06M |
| Market Cap | 4.15B |
| PE | -25.12 |
| EPS | -2.05 |
| Moving Average 50 Days | 47.04 |
| Moving Average 200 Days | 35.67 |
| Change | -0.12 |
CG Oncology Provides Updated Timeline for PIVOT-006 Phase 3 Topline Data in Intermediate-Risk NMIBC
GlobeNewswire Inc.
Jan 09, 2026 1:30 PM GMT
- PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy for intermediate-risk NMIBC now expected in 1H 2026, nearly one year ahead of schedule - First randomized registrational trial to evaluate an investigational therapy in intermedia
CG Oncology to Present at the 44th Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Jan 06, 2026 1:00 PM GMT
IRVINE, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder
SUO-CTC and CG Oncology Announce the Second Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award
GlobeNewswire Inc.
Dec 18, 2025 1:00 PM GMT
Two applicants will each receive a Grant of $50,000 to support the development of outstanding clinical cancer research to improve the treatment of NMIBCApplications for the fellowship are due on February 27, 2026 SCHAUMBURG, Ill. and IRVINE, Calif.,